Shingles, also called herpes zoster (HZ), is a painful rash that develops due to reactivation of the varicella zoster virus, which causes chicken pox. Approximately 1 in 3 individuals in the United States will develop shingles during their lifetime, with adults over 50 years of age and immunocompromised individuals being at highest risk. Recent developments in HZ prevention include a new recombinant zoster vaccine, which is now recommended as the preferred shingles vaccine in updated guidelines from the Advisory Committee on Immunization Practices (ACIP). Education regarding the most up-to-date guidelines, as well as prevention and management strategies, is essential to help prevent the potential sequelae of HZ, which can include post-herpetic neuralgia, ophthalmic involvement, and increased risk of stroke. Effective prevention and risk management strategies are particularly important for patients with immune-mediated diseases. In this CME podcast series, experts will review the clinical aspects and primary risk factors for HZ, discuss optimized use of vaccines for at-risk populations, and provide guidance on effective patient education strategies to enhance vaccine uptake.